Evaluation of Dermatomyositis

Key Clinical Triggers for Evaluation

The European League Against Rheumatism (EULAR) and American College of Rheumatology (ACR) recommend evaluating any patient presenting with characteristic skin manifestations plus proximal muscle weakness, regardless of muscle enzyme levels 1
Patients with progressive proximal muscle weakness and symmetric involvement of upper and lower extremities should be evaluated for dermatomyositis, particularly when neck flexors are weaker than extensors 1
Unexplained elevation of muscle enzymes, such as CK, LDH, AST, and ALT, even without overt weakness, warrants evaluation for dermatomyositis 1
The presence of dysphagia or esophageal dysmotility, accompanied by skin findings, requires urgent evaluation 1
Respiratory symptoms suggesting interstitial lung disease, accompanied by skin findings, require evaluation for dermatomyositis 2, 3

In children, nailfold capillary changes should be assessed with magnification, and children under 9 years may require adjusted thresholds for muscle strength scores 2, 3
Adults with dermatomyositis have a 3-8 times increased malignancy risk, requiring cancer screening at diagnosis 6

The 2017 EULAR/ACR criteria provide a scoring system to determine the probability of idiopathic inflammatory myopathy, with a score ≥5.5 indicating "probable IIM" and ≥7.5 indicating "definite IIM" 1
The presence of anti-Jo-1 antibody is assigned 3.9 points in the scoring system 5
Elevated muscle enzymes are assigned 1.3 points in the scoring system 4

Delayed diagnosis can lead to increased complications and limit treatment options, with early aggressive treatment associated with better prognosis 6, 4
Interstitial lung disease is present in approximately 8% of patients with dermatomyositis and represents a major cause of mortality, often while asymptomatic 2, 3, 4
Cardiac involvement can be life-threatening if missed, and malignancy screening is essential in adults with dermatomyositis 4, 5, 6